The Software Revolution Eating Pharma from the Inside Out

The biopharma industry just crossed a threshold nobody's talking about clearly enough. We're not in an "AI is coming" moment anymore. We're in the moment where AI stops being a future possibility and becomes the actual infrastructure of how drugs get made. And here's the thing that keeps me up at night: the software layer is now the constraint, not the biology.

Think about it. A decade ago, we worried about whether our assays would work. Now we're worried about whether our data pipelines will scale fast enough to keep up with what the science can do. That's a fundamental inversion, and it changes everything about how we should be building companies.

The 50 Percent Speed Increase Is Just Table Stakes Now

AI based clinical trials hit $1.49 billion in 2026, with platforms now preparing IND submissions 50 percent faster than traditional approaches. When I read that number, my first thought wasn't "wow, that's fast." My first thought was "okay, so what does the next 50 percent look like?" Because we've crossed into the world where speed becomes a commodity, and whoever figures out the next architectural breakthrough wins.

The real game isn't discovery speed anymore. It's the ability to compress the entire R&D cycle by changing how decisions get made. AI isn't just running molecules through a model faster. The serious players are using it to figure out which clinical protocols even matter, which patient populations will actually respond, where to run trials so you don't waste recruitment budget on dead ends. That's not marginally better. That's fundamentally different thinking.

What I'm watching is whether companies can actually operationalize this. Speed in a lab is one thing. Speed that holds up across manufacturing, regulatory, and commercial launch is another entirely. The software has to work end to end, and most organizations still can't think in those systems terms.

Gene Therapies Moving From "One Offs" to "Repeatable Medicine"

Cell and gene therapy is moving from experimental science to repeatable medicine, with the FDA's new N of 1 pathway enabling personalized CRISPR treatments. This is genuinely paradigm shifting, and I don't use that phrase lightly.

For years, gene therapies felt like artisanal medicine. You'd cure one patient, and it would be this incredible story, and then the next patient would fail because biology isn't a factory. The N of 1 pathway changes the conversation entirely. It lets you say, "Your specific mutation, your specific biology. We're going to design a treatment just for you." And crucially, the software becomes the bridge between personalization and reproducibility.

The manufacturing complexity here is insane. But here's what nobody's emphasizing enough: the software stack that coordinates all of this becomes the actual product in some sense. Your assay design, your sequencing pipelines, your CRISPR design algorithms, your manufacturing simulation tools, they all have to talk to each other perfectly or the whole thing falls apart. One hospital trying to do this? It's a research project. Ten hospitals doing it? That's industrial. And the difference between those two things is the quality of the software orchestration.

I'm genuinely curious whether anyone's building for the "gene therapy operating system" that this moment demands. Because right now it feels like everyone's cobbling together pieces and hoping it works.

Digital Twins Aren't Just Nice To Have Anymore

PwC predicts that winning pharma companies will embed AI, automation, and digital twins into every layer of the enterprise by 2026. Novartis is already using digital twin technology to simulate production processes and test changes virtually before physical implementation, reducing process optimization time.

This is where software competence becomes existential. A digital twin isn't just a simulation you run once. It's a continuous model of reality that you're constantly feeding data back into. You run a batch, you get unexpected results, the digital twin absorbs that and recalibrates. Next batch is better. It's machine learning applied to manufacturing itself.

Most pharma companies still think about manufacturing like it's something you lock down and then defend. The ones that are going to survive the next five years are the ones who think about manufacturing like it's software. Continuously updating, always learning, optimizing for edge cases before they become problems.

The insight here is that software isn't automating manufacturing. Software is making manufacturing intelligent. And there's a massive difference between those two things. One is about replacing people with robots. The other is about making the people and the robots better together.

The Patent Cliff Isn't About Patents, It's About Urgency

Biopharma M&A reached $138 billion across 129 deals in 2025, with deal values expected to remain strong in 2026 as companies backfill pipelines facing patent expirations. That's a $300 billion sales cliff looming between 2026 and 2030. And it's driving this frantic M&A activity.

But here's what I actually care about: the companies that are going to win this game aren't the ones buying the most assets. They're the ones building the software infrastructure to absorb new assets faster. When you acquire a company, you don't inherit just their molecules. You inherit their data, their workflows, their institutional knowledge. The ability to integrate all of that quickly is pure software problem. Your data models have to be compatible. Your analytical pipelines have to talk to theirs. Your decision making frameworks have to align.

Companies that have messy, siloed software systems are going to get destroyed by their own acquisitions. The integration costs are going to eat them alive. And companies that have spent the time building clean, modular, intelligent software architectures are going to move at 10x speed integrating new capabilities.

This is the real moat right now, and I think most of the industry doesn't see it yet.

AI Native Biotechs Are Playing a Different Game

Across oncology and fibrosis, companies like Iambic, Insilico and Recursion are advancing AI designed drugs into first in human and even midstage trials, signaling that end to end AI drug creation has become real and repeatable. AI native biotechs have shown materially higher phase 1 success rates while shortening discovery and development timelines by 40 to 50 percent.

These aren't just faster versions of traditional pharma. They're operating under completely different assumptions about how drugs should be discovered and developed. They don't have the legacy infrastructure that traditional pharma has. That's usually a disadvantage. Except when it's not. When the entire paradigm shifts, not having the old infrastructure becomes an advantage.

Forty to 50 percent faster is already a game changer. But what I'm actually interested in is the quality signal. Higher phase 1 success rates means they're picking better targets, better molecules, or better patients earlier. That's not luck. That's a fundamentally better approach to risk assessment.

Traditional pharma is trying to bolt AI onto existing structures. These companies were born in AI. They think about problems in AI first and then do the biology. The output quality is different, and that difference is going to compound.

The Real Conversation Nobody's Having

Forty one percent of surveyed leaders are making plans for automating entire R&D discovery workflows with intelligent AI agents. Let that sink in for a second. We're talking about autonomous systems that reason, act, and adapt within the actual creative part of drug discovery. Not just screening. Not just data crunching. The actual conceptual work.

This sounds like science fiction until you think about what an AI agent actually does. It formulates hypotheses based on literature and your experimental data. It designs experiments to test those hypotheses. It interprets the results. It updates its model. It designs the next experiment. That's basically what researchers do, except the agent can run 1000 iterations while a human researcher runs one.

The thing that terrifies and excites me in equal measure is that we don't really know what the failure modes look like yet. What if the agent converges on a solution that's locally optimal but globally wrong? What if it systematically misses creative leaps that require actual intuition? We're going to find out in real time, and the companies that move fastest might also make the most spectacular mistakes.

But they'll learn faster too, and that's what actually matters in a winner take most environment.